Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196392 | 0.87 | KIF11 (0.55) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL3188908 | 0.84 | KIF11 (0.52) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL11034545 | 0.77 | KIF11 (0.48) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL28954005 | 0.77 | KIF11 (0.48) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL1974668 | 0.77 | KIF11 (0.48) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL1149158 | 0.77 | KIF11 (0.64) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL3176030 | 0.76 | KIF11 (0.46) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL27656873 | 0.70 | KIF11 (0.62) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 | |
| SCHEMBL8361192 | 0.70 | KIF11 (0.42) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28263648 | 0.70 | KIF11 (0.55) | KIF11CYP11B1CYP11B2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | disclosed |
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | disclosed |
| WO-2017068596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-04-27 | — | — | WO | disclosed |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-12-01 | — | — | US | disclosed |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-31 | — | — | US | disclosed |
| US-5238922-A | Anticancer agents | MERCK & CO., INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0535731-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | IL17A, HSD17B7, SULT1E1 | KIF11 1550/4885CYP11B1 5/4885CYP11B2 11/4885 |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | AADAC, ABCG2, HDAC3 | KIF11 3317/4885CYP11B1 61/4885CYP11B2 32/4885 |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | AADAC, ABCG2, RICTOR | KIF11 3214/4885CYP11B1 42/4885CYP11B2 28/4885 |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | SULT1E1, IL17A, TET1 | KIF11 1467/4885CYP11B1 5/4885CYP11B2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.